You are here

Novel bispecific T cell engaging antibodies for treatment of Lyme disease

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI114214-01
Agency Tracking Number: R43AI114214
Amount: $224,849.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA13-234
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
MALVERN, PA 19355-1326
United States
DUNS: 962964990
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (610) 990-7531
Business Contact
Phone: (610) 990-7431
Research Institution

DESCRIPTION (provided by applicant): Lyme disease (LD) is the most commonly reported tick-borne illness in the United States. According to the recent Center for Disease Control and Prevention report, approximately 300,000 Lyme cases are diagnosed each year. If left untreated, the infection spreads to joints, the heart and the nervous system. In most cases, infections and associated symptoms are eliminated by antibiotic use. Following the antibiotic treatment, however, many patients have persistent or recurrent symptoms characterized by lingering fatigue, pain, or joint and muscle aches. Studies in animal models indicate that Lyme spirochetes may persist following antibiotic therapy. For those patients who do not respond antibiotics, a novel therapy based onbispecific antibodies is proposed. Bispecific T-cell engaging antibodies (BiTe) will used to redirect T cells to borrelial target cells to trigger cytotxic action by T-lymphocytes. In Phase I, single domain nanobodies to human T cell protein CD3 and L

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government